Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly concizumab prophylaxis in haemophilia A and B with or without inhibitors
2019-002641-37Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of concizumab in hemophilia A and hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Number of treated bleeding episodes. Started Feb 2020; status: terminated.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2019-002641-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002641-37.